NCT03442673CompletedPhase 2
Chemotherapy and G-CSF for Mobilization
A Randomized Phase II Trial Comparing Stem Cell Mobilization With Chemotherapy and Cytokine (G-CSF) Versus Cytokine (G-CSF) Alone in Myeloma Patients (MOCCCA-trial).
Source: ClinicalTrials.gov · Last updated 28 Mar 2025
Brief summary (registry, in English)
This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in myeloma patients.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 137 (actual)
- First submitted
- 16 Feb 2018
- Start date
- 17 Sept 2018
- Primary completion date
- 1 Mar 2023
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Diseases
- Multiple myeloma
- NCT number
- NCT03442673
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 137
- From 17 Sept 2018 to the primary completion date, 1 Mar 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with concurrent other malignant disease can be included, but previous treatment for other malignancies must have been terminated at least 2 months before registration. Endocrine treatment (such as for breast cancer) is allowed.
- The use of any anti-cancer investigational agents within 14 days prior to the expected start of trial treatment.
Other
- Pregnancy or lactating female patients.
Who the study is looking for
- Myeloma or amyloidosis patients after standard first-line induction treatment. (Additional induction regimens in refractory myeloma patients are allowed)
- Patients must be considered being clinically fit for subsequent consolidation with high-dose melphalan-based chemotherapy with autologous stem cell support.
- Patients must be aged ≥18 years.
- Female patients of child-bearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to study treatment mobilisation, and they must implement adequate measures (hormonal treatment p.o. or i.m., intra uterine surgical devices, or latex condoms) to avoid pregnancy during study treatment and for additional 12 months.
- Patients must have given voluntary written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department for Medical Oncology University Hospital/Inselspital Coordinator of this site? Confirm its status | Bern | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.